Passage Bio (PASG) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio (PASG) has outperformed Pluri (PLUR) over the past year, losing 54.3% versus a loss of 75.5%. Over five years, PLUR leads with a -95.2% price change compared with -98.1% for PASG. Pluri is the larger company by market cap ($12.6 million vs $12.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PASG | PLUR |
|---|---|---|
| Share price | $3.78 | $1.00 |
| Market cap | $12.16M | $12.61M |
| 1-day change | -1.95% | -3.85% |
| YTD return | -67.97% | -66.56% |
| 1-year return | -54.35% | -75.49% |
| 5-year return | -98.06% | -95.23% |
| EPS (TTM) | $-11.55 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.00 | $4.87 |
| 52-week low | $3.29 | $0.85 |
| Distance from 52-week high | -81.10% | -79.47% |
| Analyst consensus | buy | — |
| Avg. price target upside | +310.05% | — |
| Average volume | 26.11K | 24.97K |
| Shares outstanding | 3.22M | 12.61M |
| Employees | 24 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed PLUR by 21.1 percentage points over the past year.
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Healthcare · Biotechnology · 24 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
PASG vs PLUR FAQ
Which is bigger, Passage Bio or Pluri?
Pluri (PLUR) is larger, with a market capitalization of $12.61M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, PASG or PLUR?
PASG returned -54.35% over the past 12 months, compared with -75.49% for PLUR (price return, excluding dividends). Past performance does not predict future results.
Are Passage Bio and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.